Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Anemia is the the most frequently extradigestive symptom for Inflammatory Bowel Disease. This
is due to iron deficiency and inflammation.
Most of treatments aim to control inflammation using anti-TNF alpha therapy which should
theorically reduce anemia.
The aim of the study is to show that perfusion of iron associated to anti-TNF therapy should
reduce anemia and improve quality of life of patients.
Phase:
Phase 3
Details
Lead Sponsor:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives